Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume 23, Issue 8, Pages 995-1008
Publisher
Elsevier BV
Online
2022-07-05
DOI
10.1016/s1470-2045(22)00326-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
- (2022) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Disease Primers
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC
- (2021) Dominik Pfister et al. NATURE
- Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial
- (2021) Masatoshi Kudo et al. Liver Cancer
- Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study
- (2021) Sumanta K. Pal et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
- (2021) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
- (2021) Ann-Lii Cheng et al. JOURNAL OF HEPATOLOGY
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
- (2021) Thomas Yau et al. LANCET ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
- (2020) Michael S Lee et al. LANCET ONCOLOGY
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma
- (2019) Yaojie Fu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma
- (2019) William M. Kamp et al. Scientific Reports
- Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence
- (2019) Paulo Bergerot et al. MOLECULAR CANCER THERAPEUTICS
- Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
- (2018) Jorge A. Marrero et al. HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting VEGF/VEGFR to Modulate Antitumor Immunity
- (2018) Ju Yang et al. Frontiers in Immunology
- Epidemiology and Management of Hepatocellular Carcinoma
- (2018) Laura Kulik et al. GASTROENTEROLOGY
- Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
- (2012) Hashem B. El-Serag GASTROENTEROLOGY
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
- (2011) F. M. Yakes et al. MOLECULAR CANCER THERAPEUTICS
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search